GPC3 CAR-T cell therapy for advanced liver cancer
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced liver cancer (BCLC stage B or C) that cannot be removed by surgery.
- You have had at least one prior treatment (like chemotherapy, targeted therapy, or immunotherapy) that stopped working.
- Your liver function is relatively good (Child-Pugh score of 7 or less).
- Your cancer cells test positive for a protein called GPC3.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This trial tests a new treatment using your own immune cells, modified to better find and attack liver cancer cells. It is for people whose liver cancer has returned or spread and cannot be removed with surgery.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.